Key takeaways
- BPC-157 has limited human evidence, including randomized studies reported as conference abstracts, while FDA staff found no clinical studies that gave KPV to people.
- The US Department of Health and Human Services names both peptides in its October 2026 draft compounding policy, which the Federal Register notice says is not binding.
- WADA names BPC-157 in class S0 and prohibits it at all times; KPV is not named on the 2026 or 2027 List, but WADA warns that unnamed peptides may still be prohibited.
01BPC-157 vs KPV in one table
| Question | BPC-157 | KPV |
|---|---|---|
| Identity | Synthetic 15-amino-acid peptide | Three-amino-acid peptide, lysine–proline–valine, from the sequence of alpha-melanocyte-stimulating hormone |
| Evidence tier | Mostly animal research (T3), with lab studies (T4) and limited human evidence (T2; randomized data in conference abstracts) | Animal (T3) and lab studies (T4), not evidence of an effect in people |
| Human data | Small studies and randomized data reported in conference abstracts; material sold online is not the material studied | FDA staff found no clinical studies that gave KPV to people in their July 2026 review |
| United States | FDA staff found no approved drug containing it; named in the October 2026 HHS draft compounding policy, which is not binding | FDA staff found no approved drug containing it; named in the October 2026 HHS draft compounding policy, which is not binding |
| United Kingdom | Marketing authorisation not confirmed here; MHRA classifies finished products case by case | Marketing authorisation not confirmed here; MHRA classifies finished products case by case |
| Australia | Named in Schedule 4 and Appendix D, clause 5, of the October 2026 Poisons Standard; scheduling is not approval | The TGA says “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” KPV has no entry by name in the October 2026 Poisons Standard. We draw no scheduling conclusion of our own. |
| Sport | WADA names BPC-157 in S0 on the 2026 and 2027 Lists; prohibited at all times | KPV is not named on either List, but WADA warns that unnamed peptides may still be prohibited |
Status as of 21 November 2026. The 2027 World Anti-Doping Agency (WADA) List comes into force on 1 January 2027.
02What differs in the research?
If you searched “kpv vs bpc-157”, start with who or what was studied. A study in living participants is different from one in lab-grown human cells, even when both are described as using human material.
BPC-157 in people
FDA staff summarise a placebo-controlled study with 32 healthy participants randomised, reported in meeting abstracts in 2002 and 2003. The abstracts cover tolerability and how the compound was processed in the body. We found no full paper of the study. Material sold online is not the material studied.
BPC-157 in rats
Staresinic and colleagues studied rats with a surgically cut Achilles tendon in 2003 (T3). That design does not show an effect in people.
KPV in the lab
Dalmasso and colleagues studied KPV in cultured human intestinal and immune cells (T4) and in mouse models (T3) in a 2008 paper. Neither is evidence of an effect in people.
FDA staff also summarise a 2005 randomized, placebo-controlled BPC-157 study: 53 people were randomised and 46 completed it. That study is known from a meeting abstract too. Material sold online is not the material studied in either trial. The BPC-157 research guide separates those abstracts from the other human reports.
03What stayed the same in US policy?
Both peptides followed the same US compounding timeline. A category change, an advisory vote, and a draft enforcement policy are different actions.
- September 2023 to 22 April 2026Category 2
HHS says both were in FDA’s Category 2 during this period. HHS says neither placement nor removal changed their status under section 503A.
- July 2026Advisory votes
FDA drug-centre staff recommended against adding either peptide to the list of bulk ingredients for section 503A compounding. HHS records that the advisory committee voted in favour of listing both. The votes were recommendations.
- 30 October 2026Draft policy notice
The Federal Register published notice of a draft HHS policy. It states that HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians in the circumstances specified. The notice says the draft is not binding. HHS names both peptides and specifies one listed active ingredient per preparation and a patient-specific prescription.
In the UK, the Medicines and Healthcare products Regulatory Agency assesses a finished product’s presentation and function case by case. In Australia, the Poisons Standard is a scheduling document, not a list of approved products. In sport, S0 covers pharmacological substances not addressed elsewhere on the List that have no current government approval for human therapeutic use.
04What we don’t know
- How they compare in people. The studies described here do not compare the two peptides in people, so they do not support a ranking.
- Their safety profiles in people. In July 2026, FDA staff found insufficient clinical safety information to characterise BPC-157’s safety profile and said potential human safety risks for KPV were unknown because they had identified no clinical studies or human exposure data.
- What a particular vial contains. A name on a label or a purity percentage does not establish identity. The lab report needs to match the lot and show a separate identity result.
How the lab report distinguishes them. FDA staff give different molecular weights for the free bases: 1419.5 g/mol for BPC-157 and 342.43 g/mol for KPV. The expected result must match the chemical form being tested. For how to find the identity result and distinguish it from purity, see how to read a certificate of analysis (COA).
This is a plain-English summary of public documents and studies as of 21 November 2026, not legal or medical advice.